VistaGen Therapeutics Announces Issuance of Two U.S. Patents

Strategic Insights -

VistaGen Therapeutics, a biotechnology company, has announced the issuance of two new U.S. patents, further enhancing its intellectual property portfolio and providing additional protection for its proprietary research and development activities. The patents, U.S. Patent 7,763,466 and U.S. Patent 7,955,849, cover methods for producing endoderm and mesoderm cells using activin and serum-free culture conditions. These patents solidify VistaGen's growing IP portfolio and expand the application of its activin-driven pluripotent stem cell differentiation technology to include a broader range of tissues and organ systems.

Key Takeaways:

  • VistaGen Therapeutics has announced the issuance of two new U.S. patents, U.S. Patent 7,763,466 and U.S. Patent 7,955,849, which cover methods for producing endoderm and mesoderm cells using activin and serum-free culture conditions.
  • The patents further enhance VistaGen's intellectual property portfolio and provide additional protection for its proprietary research and development activities.
  • The methods described in the patents are expected to have significant commercial value and expand the application of VistaGen's activin-driven pluripotent stem cell differentiation technology to include a broader range of tissues and organ systems.
  • VistaGen's Chief Executive Officer, Shawn K. Singh, stated that strong and enforceable intellectual property rights are critical components of the company's plan to optimize the commercial potential of its Human Clinical Trials in a Test Tube platform.
  • The patents are part of a large and growing number of patents granted in territories outside the U.S., giving VistaGen proprietary rights to its intellectual property.

Statistics:

  • Two new U.S. patents have been issued to VistaGen Therapeutics, specifically U.S. Patent 7,763,466 and U.S. Patent 7,955,849.
  • The patents cover methods for producing endoderm and mesoderm cells using activin and serum-free culture conditions.
  • The patents are subject to exclusive licenses to VistaGen on a worldwide basis through an agreement with Mount Sinai School of Medicine.
  • The patents have significant commercial value and are expected to expand the application of VistaGen's activin-driven pluripotent stem cell differentiation technology.
  • VistaGen has a large and growing number of patents granted in territories outside the U.S.

Sources:

  • Marketing Weekly News editors.
  • VerticalNews.com.